Investigational Drug IACS-6274 Shows Activity in Advanced Ovarian Cancer Clinical Trial
In a phase I trial of fourteen patients with advanced ovarian cancer, the investigational glutaminase-1 inhibitor IACS-6274 combined with bevacizumab ...
In a phase I trial of fourteen patients with advanced ovarian cancer, the investigational glutaminase-1 inhibitor IACS-6274 combined with bevacizumab ...
We bring you the latest biotechnology news from best research centers and universities around the world. Check our website.
Bioengineer.org © Copyright 2023 All Rights Reserved.
Bioengineer.org © Copyright 2023 All Rights Reserved.